Latest advanced prostate cancer Stories
A team of researchers at Fred Hutchinson Cancer Research Center and the University of Washington has conducted the first comprehensive assessment of every gene in the genome of advanced, lethal prostate cancer.
UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.
TARRYTOWN, N.Y., July 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S.
WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E.
PARSIPPANY, N.J., May 6, 2011 /PRNewswire/ -- Ferring Pharmaceuticals Inc., the makers of FIRMAGONÂ® (degarelix for injection), a hormone antagonist therapy for advanced prostate cancer, has joined the race to end prostate cancer as an official sponsor of the Great Prostate Cancer ChallengeÂ®, the fastest growing men's health event series in the United States.
SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
SAN FRANCISCO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc.
SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
- The act of sweetening by admixture of some saccharine substance.